Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896984 · ClinicalTrials.gov registry record
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 346
- Enrollment target
NCT03896984 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 346 participants.
The verdict
NCT03896984 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 346 participants
- Enrollment target
Study Summary
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line treatment). Additionally the researchers are also interested in the occurrence of bone fractures and other skeletal events. Basis for this study will be the US based Flatiron database which provides access to clinical data for cancer patients.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Radium-223 (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2020-12-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896984
The ClinicalTrials.gov registry entry for NCT03896984 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT03896984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03896984 about?
NCT03896984 is a clinical study titled "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).". In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line tre...
What is the current status of trial NCT03896984?
This trial is currently completed. The enrollment target is 346 participants. The study started on 2019-03-18. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03896984?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Radium-223 (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT03896984?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.